• 四川省腫瘤醫(yī)院（成都610041）;

目的  探討新輔助化療在晚期乳腺癌治療中的遠(yuǎn)期臨床效果。
方法  對(duì)31例Ⅲ、Ⅳ期的乳腺癌患者行新輔助化療，手術(shù)前行2周期的CAF方案化療〔CTX 500 mg/m2靜脈推注（第1、8天）, 5-FU 500 mg/m2靜脈推注（第1、8天）,ADM 30 mg/m2靜脈推注（第1天）,每21天為1周期〕，并與同期未行任何術(shù)前治療的可手術(shù)的30例Ⅲa期患者作對(duì)比分析。
結(jié)果  新輔助化療組的總有效率為87.1%（27/31），有61.3%（19/31）的患者分期降低，其中6例降為Ⅲa期，8例降為Ⅱb期，4例降為Ⅱa期，1例降為0期，臨床完全緩解1例，無(wú)病理完全緩解。新輔助化療組的無(wú)病生存期為56.3個(gè)月，明顯高于未行化療組的43.5個(gè)月（P＜0.05），新輔助化療組的5年無(wú)病生存率為38.7%，略高于未化療組的33.3%，兩組間差異無(wú)顯著性意義。
結(jié)論  新輔助化療能降低晚期乳腺癌患者的分期，為手術(shù)創(chuàng)造最佳機(jī)會(huì)，能明顯延長(zhǎng)晚期乳腺癌患者的無(wú)病生存期，減少或延緩腫瘤的復(fù)發(fā)、轉(zhuǎn)移。

引用本文： 李卉,廖傳貴,何小梅. 晚期乳腺癌新輔助化療的臨床報(bào)告. 中國(guó)普外基礎(chǔ)與臨床雜志, 2004, 11(1): 20-21. doi: 復(fù)制

版權(quán)信息： ?四川大學(xué)華西醫(yī)院華西期刊社《中國(guó)普外基礎(chǔ)與臨床雜志》版權(quán)所有，未經(jīng)授權(quán)不得轉(zhuǎn)載、改編

1. Hayward JL, Carbone PP, Heusen JC, et al. Assessment of response to therapy in advanced breast cancer [J]. Br J Cancer, 1977; 35(3)∶292.
2. Wang HC, Lo SS. Future prospects of neoadjuvant chemotherapy in treatment of primary breast cancer [Ｊ]. Semin Surg Oncol, 1996; 12(1)∶59.
3. Gradishar WJ. Recently initiated studies: neoadjuvant treatments in the next century [Ｊ]. Semin Oncol, 1999; 26(1)∶26.
4. Sapunar F, Smith IE. Neoadjuvant chemotherapy for breast cancer [Ｊ]. Ann Med, 2000; 32(1)∶43.
5. Conte PF, Latreille J, Mauriac L, et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group [Ｊ]. J Clin Oncol, 1996; 14(9)∶2552.
6. Bonadonna G, Valagussa P, Zucali R, et al. Primary chemotherapy in surgically resectable breast cancer [Ｊ]. CA Cancer J Clin, 1995; 45(4)∶227.
  1. 1. Hayward JL, Carbone PP, Heusen JC, et al. Assessment of response to therapy in advanced breast cancer [J]. Br J Cancer, 1977; 35(3)∶292.
  2. 2. Wang HC, Lo SS. Future prospects of neoadjuvant chemotherapy in treatment of primary breast cancer [Ｊ]. Semin Surg Oncol, 1996; 12(1)∶59.
  3. 3. Gradishar WJ. Recently initiated studies: neoadjuvant treatments in the next century [Ｊ]. Semin Oncol, 1999; 26(1)∶26.
  4. 4. Sapunar F, Smith IE. Neoadjuvant chemotherapy for breast cancer [Ｊ]. Ann Med, 2000; 32(1)∶43.
  5. 5. Conte PF, Latreille J, Mauriac L, et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group [Ｊ]. J Clin Oncol, 1996; 14(9)∶2552.
  6. 6. Bonadonna G, Valagussa P, Zucali R, et al. Primary chemotherapy in surgically resectable breast cancer [Ｊ]. CA Cancer J Clin, 1995; 45(4)∶227.